Stock Analiz

Cullinan Therapeutics, Inc. CGEM

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$10.28Market cap $667M
Open the interactive analysis →

Cullinan Therapeutics, Inc. (CGEM) is a healthcare company listed in the US with a market value of about $667M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -24%.

About Cullinan Therapeutics

Cullinan Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 1 of the last 6 years in our data. Its share count rose by 39% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B2.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-24.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-346.1%
ROIC (5-yr avg.)-24.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue————$19M$0
Net income-$220M-$167M-$153M$111M-$66M-$52M
Free cash flow-$176M-$145M-$134M-$128M-$43M-$30M
EPS (diluted)$-3.39—$-3.69$2.38$-1.52$-2.60
Net margin————-346.1%—
ROIC-58.7%-26.3%-38.3%19.3%-15.9%-23.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $34.27, 233% above the current price; targets range from $27.00 to $44.00; the consensus rating is “Strong buy”; expected EPS is $-3.01 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Cullinan Therapeutics pay a dividend?

Not currently.

Is Cullinan Therapeutics a good stock to buy?

We do not give buy or sell advice. Cullinan Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.